NTRK2 and neurodegenerative disease: The exploration of the differential expression of full vs. truncated isoforms in models of neurodegenerative diseases represents an exciting research direction, especially in light of reports showing that the manipulation of the TrkB:TrkB.T1 ratio acts to modify disease onset [70,71,72].